DaVita (DaVita) Beta

: 1.00 (As of Today)

View and export this data going back to 1995. Start your Free Trial

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-16), DaVita's Beta is 1.00.

DaVita Beta Historical Data

The historical data trend for DaVita's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beta

2.13

1.26

1.08

0.60

0.89

DaVita Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beta																0.60	0.72	0.79	0.83	0.89

Competitive Comparison

For the Medical Care Facilities subindustry, DaVita's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DaVita Beta Distribution

For the Healthcare Providers & Services industry and Healthcare sector, DaVita's Beta distribution charts can be found below:

* The bar in red indicates where DaVita's Beta falls into.

DaVita Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

DaVita (NYSE:DVA) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

DaVita Beta Related Terms

Thank you for viewing the detailed overview of DaVita's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

DaVita (DaVita) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (NYSE:DVA) » Definitions » Beta

Comparable Companies

Traded in Other Exchanges

TRL:Germany TRL:Germany DVAI34:Brazil

Address

2000 16th Street, Denver, CO, USA, 80202

Website

https://www.davita.com

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Executives

Christopher Michael Berry	officer: Chief Accounting Officer	C/O SONDER HOLDINGS INC., 101 15TH ST., SAN FRANCISCO CA 94103
Kathleen Alyce Waters	officer: Chief Legal Officer	C/O DAVITA INC., 2000 16TH STREET, DENVER CO 80202
Wendy Lee Schoppert	director	6105 TRENTON LANE NORTH, MINNEAPOLIS MN 55442
Phyllis R Yale	director
Javier Rodriguez	officer: Chief Executive Officer, DKC	601 HAWAII ST., EL SEGUNDO CA 90245
Barbara J Desoer	director	CITIGROUP INC., 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
James O Hearty	officer: Chief Compliance Officer	2000 16TH STREET, DENVER CO 80202
Charles Berg	director, officer: Executive Chair, DMG	48 MONROE TURNPIKE, TRUMBULL CT 06611
John M Nehra	director	1119 ST PAUL ST, BALTIMORE MD 21202
Adam H Schechter	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Michael David Staffieri	officer: Chief Operating Officer, DKC	2000 16TH STREET, DENVER CO 80202
Jason M. Hollar	director	3333 BEVERLY ROAD, HOFFMAN ESTATES IL 60179
Paula A Price	director	ONE CVS DRIVE, WOONSOCKET RI 02895
Pamela M Arway	director	601 HAWAII ST., EL SEGUNDO CA 90245
Gregory J. Moore	director	130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601